|
Gene: ETV3 |
Gene summary for ETV3 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ETV3 | Gene ID | 2117 |
Gene name | ETS variant transcription factor 3 | |
Gene Alias | METS | |
Cytomap | 1q23.1 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P41162 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2117 | ETV3 | LZE4T | Human | Esophagus | ESCC | 1.17e-02 | 2.78e-01 | 0.0811 |
2117 | ETV3 | LZE7T | Human | Esophagus | ESCC | 9.47e-06 | 2.05e-01 | 0.0667 |
2117 | ETV3 | LZE8T | Human | Esophagus | ESCC | 4.49e-04 | 1.44e-01 | 0.067 |
2117 | ETV3 | LZE20T | Human | Esophagus | ESCC | 2.13e-03 | 1.29e-01 | 0.0662 |
2117 | ETV3 | LZE21T | Human | Esophagus | ESCC | 1.37e-02 | 3.66e-01 | 0.0655 |
2117 | ETV3 | P1T-E | Human | Esophagus | ESCC | 1.70e-09 | 2.53e-01 | 0.0875 |
2117 | ETV3 | P2T-E | Human | Esophagus | ESCC | 1.04e-25 | 3.70e-01 | 0.1177 |
2117 | ETV3 | P4T-E | Human | Esophagus | ESCC | 8.95e-09 | 9.20e-02 | 0.1323 |
2117 | ETV3 | P5T-E | Human | Esophagus | ESCC | 7.16e-06 | 2.11e-01 | 0.1327 |
2117 | ETV3 | P8T-E | Human | Esophagus | ESCC | 4.89e-17 | 1.82e-01 | 0.0889 |
2117 | ETV3 | P9T-E | Human | Esophagus | ESCC | 2.47e-19 | 2.79e-01 | 0.1131 |
2117 | ETV3 | P10T-E | Human | Esophagus | ESCC | 1.88e-16 | 6.62e-02 | 0.116 |
2117 | ETV3 | P11T-E | Human | Esophagus | ESCC | 6.36e-10 | 2.27e-01 | 0.1426 |
2117 | ETV3 | P12T-E | Human | Esophagus | ESCC | 1.83e-17 | 1.07e-01 | 0.1122 |
2117 | ETV3 | P15T-E | Human | Esophagus | ESCC | 2.12e-16 | 3.46e-01 | 0.1149 |
2117 | ETV3 | P16T-E | Human | Esophagus | ESCC | 1.83e-13 | 1.44e-01 | 0.1153 |
2117 | ETV3 | P17T-E | Human | Esophagus | ESCC | 6.44e-03 | 2.80e-02 | 0.1278 |
2117 | ETV3 | P20T-E | Human | Esophagus | ESCC | 3.47e-04 | 2.80e-01 | 0.1124 |
2117 | ETV3 | P21T-E | Human | Esophagus | ESCC | 7.17e-13 | 1.81e-01 | 0.1617 |
2117 | ETV3 | P22T-E | Human | Esophagus | ESCC | 7.97e-23 | 5.94e-02 | 0.1236 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 3 4 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ETV3 | insertion | Frame_Shift_Ins | novel | c.573_574insCATTTCC | p.Ser192HisfsTer12 | p.S192Hfs*12 | P41162 | protein_coding | TCGA-BG-A0MS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD | ||
ETV3 | insertion | Frame_Shift_Ins | novel | c.573_574insCC | p.Ser192ProfsTer39 | p.S192Pfs*39 | P41162 | protein_coding | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
ETV3 | insertion | Frame_Shift_Ins | novel | c.571_572insAT | p.Leu191HisfsTer40 | p.L191Hfs*40 | P41162 | protein_coding | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
ETV3 | insertion | Frame_Shift_Ins | novel | c.573_574insCATTTCC | p.Ser192HisfsTer12 | p.S192Hfs*12 | P41162 | protein_coding | TCGA-BS-A0UJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
ETV3 | insertion | Frame_Shift_Ins | novel | c.573_574insCATTTCC | p.Ser192HisfsTer12 | p.S192Hfs*12 | P41162 | protein_coding | TCGA-BS-A0UT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
ETV3 | insertion | Frame_Shift_Ins | novel | c.573_574insCC | p.Ser192ProfsTer39 | p.S192Pfs*39 | P41162 | protein_coding | TCGA-D1-A0ZU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | ||
ETV3 | insertion | Frame_Shift_Ins | novel | c.571_572insAT | p.Leu191HisfsTer40 | p.L191Hfs*40 | P41162 | protein_coding | TCGA-D1-A0ZU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | ||
ETV3 | SNV | Missense_Mutation | c.823T>C | p.Ser275Pro | p.S275P | P41162 | protein_coding | tolerated(0.47) | benign(0.019) | TCGA-CC-A3MC-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
ETV3 | SNV | Missense_Mutation | novel | c.757N>T | p.Pro253Ser | p.P253S | P41162 | protein_coding | deleterious(0) | probably_damaging(0.948) | TCGA-RC-A7SH-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
ETV3 | SNV | Missense_Mutation | c.43G>C | p.Gly15Arg | p.G15R | P41162 | protein_coding | deleterious(0.03) | possibly_damaging(0.88) | TCGA-86-8358-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |